Drug Trial Radar · NCT01755676
Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults
Last checked: Nov 20, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
638
Actual
Start
Sep 2016
Primary completion
Dec 2017
Study completion Dec 21, 2017
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Dec 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.
Conditions
- Obesity
Interventions
Orlistat 60 mgDrug
1 tablet 3 times a day
PlaceboOther
1 tablet 3 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Orlistat 60 mg associated with diet and exercise in relation to placebo associated with diet and exercise in obesity treatment based on weight loss.Time frame: 112 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Centro de Medicina Reprodutiva Dr Carlos Isaia Filho
Porto Alegre, Rio Grande do Sul, Brazil
Loema
Campinas, São Paulo, Brazil
Allergisa
Campinas, São Paulo, Brazil
CIPMED
Jaú, São Paulo, Brazil
Marcio Antonio Pereira Clinica de Endocrinologia
São José dos Campos, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.